I

t looks like there won’t be any Yelp reviewscolor-coded drugs, or seasteading in the Food and Drug Administration’s future. Instead, President Donald Trump is going with the establishment candidate — and the biotech industry couldn’t be more relieved.

Dr. Scott Gottlieb, a former deputy commissioner at FDA who also has a Wall Street pedigree, is Trump’s nominee to lead the agency, ending months of speculation and consternation among biotech insiders.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories